Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials

Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the treatment of schizophrenia, has a novel mechanism of action that may confer beneficial effects with improved tolerability. This pooled analysis of three randomized, double-blind, placebo-controlled trials was con...

Descripción completa

Detalles Bibliográficos
Autores principales: Kane, John M, Durgam, Suresh, Satlin, Andrew, Vanover, Kimberly E, Chen, Richard, Davis, Robert, Mates, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322041/
https://www.ncbi.nlm.nih.gov/pubmed/34054112
http://dx.doi.org/10.1097/YIC.0000000000000371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322041/
https://www.ncbi.nlm.nih.gov/pubmed/34054112
http://dx.doi.org/10.1097/YIC.0000000000000371

Ejemplares similares